<DOC>
	<DOCNO>NCT02500784</DOCNO>
	<brief_summary>The purpose study test effect long-term therapeutic dos formoterol , ) cerebrospinal fluid ( CSF ) tau level , Amyloid Beta protein 40/42 level CSF , b ) cognitive function people mild moderate Alzheimer ' Disease ( AD ) .</brief_summary>
	<brief_title>Improving Beta-2 Adrenergic Signaling Alzheimer 's Disease</brief_title>
	<detailed_description>The purpose study test effect long-term therapeutic dos formoterol , ) cerebrospinal fluid CSF tau level , A-beta amyloid protein 40/42 level , b ) cognitive function : NE-ergic neuron undergo significant degeneration AD . This system play significant role cognition . Recent study indicate increase NE level brain would significantly improve microglia migration clearance A-beta amyloid protein 40/42 level mouse model AD . The investigator plan test whether long- term daily treatment inhale formoterol solution would improve structure function hippocampal neuron AD . Study Design : Randomization initiation experimental treatment : All participant give formoterol daily 52 week . The active regimen initiate ( 20 micro gram , BID ) . The dose decrease evidence side effect , include cardiac respiratory alteration change , gastro-intestinal disturbance neurological issue .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Males female age 5085 , Mildtomoderate AD ( NINCDS/ADRDA criterion probable AD use establish AD diagnosis ) . MMSE 1626 . NonAD dementia significant neurological disease Parkinson 's disease , stroke , brain tumor , multiple sclerosis , seizure disorder , focal brain lesion , head injury loss consciousness . Hypothyroidism , congestive heart failure ( New York Heart Association Class III IV ) , significant extrapyramidal symptom neurological examination , serum creatinine &gt; 1.3 mg/dl , significant arrhythmias conduction defect abnormality ECG , Use another beta2 adrenergic drug within last 2 month . Residence longterm care facility . Evidence significant clinical disorder laboratory find render person unsuitable receive investigational new drug . Known hypersensitivity prior exposure formoterol . Active asthma family history asthma .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>